Journal of Musculoskeletal Trauma

Review Article

Romosozumab: A Novel Agent in the Management of Osteoporosis: Nam Hoon Moon, Won Chul Shin, Jae Hoon Jang; J Korean Fract Soc 2021;34(4):148-153. Published online October 31, 2021; DOI: https://doi.org/10.12671/jkfs.2021.34.4.148

With the discovery of screlostin as a pivotal player in bone metabolism, a novel medication targeting sclerostin has been introduced. Romosozumab, a humanized anti-sclerostin monoclonal antibody, is a unique approach to the treatment of osteoporosis that inhibits sclerostin, a key regulator that has the dual properties of promoting bone formation and inhibiting bone resorption. Romosozumab has been shown to be superior to conventional agents, in increasing bone mineral density and preventing osteoporotic fractures. Romosozumab may also be effective in the management of treatment-resistant osteoporosis and in the prevention of osteoporotic fractures in the very high risk population. However, further studies are necessary as there is insufficient data on its clinical efficacy and safety.

Citations

Citations to this article as recorded by

Bone Bridge Effect for the Treatment of Acute Osteoporotic Vertebral Compression Fractures: A Multistrategic Approach Using an Anabolic Agent
Ja-Yeong Yoon, Sung-Min Kim, Seong-Hwan Moon, Hak-Sun Kim, Kyung-Soo Suk, Si-Young Park, Ji-Won Kwon, Byung Ho Lee
Yonsei Medical Journal.2026; 67(6): 492. CrossRef
The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II
Dong Ock Lee, Yeon Hee Hong, Moon Kyoung Cho, Young Sik Choi, Sungwook Chun, Youn-Jee Chung, Seung Hwa Hong, Kyu Ri Hwang, Jinju Kim, Hoon Kim, Dong-Yun Lee, Sa Ra Lee, Hyun-Tae Park, Seok Kyo Seo, Jung-Ho Shin, Jae Yen Song, Kyong Wook Yi, Haerin Paik, J
Journal of Menopausal Medicine.2024; 30(2): 55. CrossRef

1,321 View
11 Download
2 Crossref

First
Prev
Page of 1
Next
Last

Search